EQUITY RESEARCH MEMO

Cymed Ostomy

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)55/100

Cymed Ostomy is a privately held U.S. medical device company specializing in ostomy care products, with a focus on its proprietary MicroSkin® adhesive barrier technology. Founded in 2003 and headquartered in Portland, Oregon, the company serves individuals with ileostomies, colostomies, and urostomies. Its core product line leverages a thin, stretchable, hypoallergenic polyurethane film that provides a secure yet gentle seal, enhancing comfort and durability for daily use. Despite a lack of disclosed funding or valuation, Cymed Ostomy has established a niche in the ostomy market by differentiating its products through superior skin-friendliness and flexibility compared to traditional hydrocolloid-based barriers. The company operates in the competitive medical devices category and is listed on biopharmguy.com, indicating active presence in the industry.

Upcoming Catalysts (preview)

  • Q3 2026Launch of next-generation MicroSkin pouch with enhanced adhesion70% success
  • Q4 2026Partnership with major hospital group for distribution expansion50% success
  • Q2 2026FDA 510(k) clearance for extended-wear urostomy pouch65% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)